377 related articles for article (PubMed ID: 18021371)
1. The value and correlation between PRL-3 expression and matrix metalloproteinase activity and expression in human gliomas.
Kong L; Li Q; Wang L; Liu Z; Sun T
Neuropathology; 2007 Dec; 27(6):516-21. PubMed ID: 18021371
[TBL] [Abstract][Full Text] [Related]
2. Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas.
Forsyth PA; Wong H; Laing TD; Rewcastle NB; Morris DG; Muzik H; Leco KJ; Johnston RN; Brasher PM; Sutherland G; Edwards DR
Br J Cancer; 1999 Apr; 79(11-12):1828-35. PubMed ID: 10206300
[TBL] [Abstract][Full Text] [Related]
3. Testican 2 abrogates inhibition of membrane-type matrix metalloproteinases by other testican family proteins.
Nakada M; Miyamori H; Yamashita J; Sato H
Cancer Res; 2003 Jun; 63(12):3364-9. PubMed ID: 12810672
[TBL] [Abstract][Full Text] [Related]
4. Expression of MMP2, MMP9, MT1-MMP, TIMP1, and TIMP2 mRNA in valvular lesions of the heart.
Soini Y; Satta J; Määttä M; Autio-Harmainen H
J Pathol; 2001 Jun; 194(2):225-31. PubMed ID: 11400152
[TBL] [Abstract][Full Text] [Related]
5. Quantitative immunohistochemical and in situ hybridization analysis of metalloproteinases in prostate cancer.
Cardillo MR; Di Silverio F; Gentile V
Anticancer Res; 2006; 26(2A):973-82. PubMed ID: 16619495
[TBL] [Abstract][Full Text] [Related]
6. In situ gene expression and localization of metalloproteinases MMP1, MMP2, MMP3, MMP9, and their inhibitors TIMP1 and TIMP2 in human renal cell carcinoma.
Bhuvarahamurthy V; Kristiansen GO; Johannsen M; Loening SA; Schnorr D; Jung K; Staack A
Oncol Rep; 2006 May; 15(5):1379-84. PubMed ID: 16596214
[TBL] [Abstract][Full Text] [Related]
7. Differential expression and localization of TIMP-1 and TIMP-4 in human gliomas.
Groft LL; Muzik H; Rewcastle NB; Johnston RN; Knäuper V; Lafleur MA; Forsyth PA; Edwards DR
Br J Cancer; 2001 Jul; 85(1):55-63. PubMed ID: 11437402
[TBL] [Abstract][Full Text] [Related]
8. Platelet-derived growth factor receptor-beta is induced during tumor development and upregulated during tumor progression in endothelial cells in human gliomas.
Plate KH; Breier G; Farrell CL; Risau W
Lab Invest; 1992 Oct; 67(4):529-34. PubMed ID: 1434531
[TBL] [Abstract][Full Text] [Related]
9. Tumor cell-matrix interaction: pericellular matrix degradation and metastasis.
Okada Y
Verh Dtsch Ges Pathol; 2000; 84():33-42. PubMed ID: 11217446
[TBL] [Abstract][Full Text] [Related]
10. Increased extracellular matrix remodeling is associated with tumor progression in human hepatocellular carcinomas.
Théret N; Musso O; Turlin B; Lotrian D; Bioulac-Sage P; Campion JP; Boudjéma K; Clément B
Hepatology; 2001 Jul; 34(1):82-8. PubMed ID: 11431737
[TBL] [Abstract][Full Text] [Related]
11. Expression of matrix metalloproteinases MMP-1, MMP-11 and MMP-19 is correlated with the WHO-grading of human malignant gliomas.
Stojic J; Hagemann C; Haas S; Herbold C; Kühnel S; Gerngras S; Roggendorf W; Roosen K; Vince GH
Neurosci Res; 2008 Jan; 60(1):40-9. PubMed ID: 17980449
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of PRL-3 expression, and its correlation with angiogenesis and invasion in hepatocellular carcinoma.
Zhao WB; Li Y; Liu X; Zhang LY; Wang X
Int J Mol Med; 2008 Aug; 22(2):187-92. PubMed ID: 18636172
[TBL] [Abstract][Full Text] [Related]
13. [CDK1 expression and effects of CDK1 silencing on the malignant phenotype of glioma cells].
Chen H; Huang Q; Zhai DZ; Dong J; Wang AD; Lan Q
Zhonghua Zhong Liu Za Zhi; 2007 Jul; 29(7):484-8. PubMed ID: 18069625
[TBL] [Abstract][Full Text] [Related]
14. Ezrin expression in tissue microarray of primary and recurrent gliomas.
Tynninen O; Carpén O; Jääskeläinen J; Paavonen T; Paetau A
Neuropathol Appl Neurobiol; 2004 Oct; 30(5):472-7. PubMed ID: 15488023
[TBL] [Abstract][Full Text] [Related]
15. Expression levels of melanoma inhibitory activity correlate with time to progression in patients with high-grade glioma.
Hau P; Ruemmele P; Kunz-Schughart LA; Doerfelt A; Hirschmann B; Lohmeier A; Koch H; Mueller A; Bogdahn U; Bosserhoff AK
Oncol Rep; 2004 Dec; 12(6):1355-64. PubMed ID: 15547763
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of membrane-type matrix metalloproteinase-1 is correlated with poor prognosis in patients with osteosarcoma.
Uchibori M; Nishida Y; Nagasaka T; Yamada Y; Nakanishi K; Ishiguro N
Int J Oncol; 2006 Jan; 28(1):33-42. PubMed ID: 16327977
[TBL] [Abstract][Full Text] [Related]
17. Elevated membrane-type matrix metalloproteinases in gliomas revealed by profiling proteases and inhibitors in human cancer cells.
Nuttall RK; Pennington CJ; Taplin J; Wheal A; Yong VW; Forsyth PA; Edwards DR
Mol Cancer Res; 2003 Mar; 1(5):333-45. PubMed ID: 12651907
[TBL] [Abstract][Full Text] [Related]
18. Activation ratio of MMP-2 and expression of MT1-MMP are correlated in thymic epithelial tumours.
Wang Y; Xu HT; Ueda Y; Shimasaki M; Wang EH
Pathology; 2007 Oct; 39(5):486-90. PubMed ID: 17886098
[TBL] [Abstract][Full Text] [Related]
19. Expression of MMP-2, MMP-7, MMP-9, MMP-10 and MMP-11 in human astrocytic and oligodendroglial gliomas.
Thorns V; Walter GF; Thorns C
Anticancer Res; 2003; 23(5A):3937-44. PubMed ID: 14666700
[TBL] [Abstract][Full Text] [Related]
20. Expression and prognostic role of MMP2, MMP9, MMP13, and MMP14 matrix metalloproteinases in sinonasal and oral malignant melanomas.
Kondratiev S; Gnepp DR; Yakirevich E; Sabo E; Annino DJ; Rebeiz E; Laver NV
Hum Pathol; 2008 Mar; 39(3):337-43. PubMed ID: 18045645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
